Literature DB >> 19360353

Down-regulation of myopodin expression reduces invasion and motility of PC-3 prostate cancer cells.

Ariane De Ganck1, Veerle De Corte, Erik Bruyneel, Marc Bracke, Joel Vandekerckhove, Jan Gettemans.   

Abstract

Enhanced motility of cancer cells by remodelling of the actin cytoskeleton is crucial in the process of cancer cell invasion and metastasis. Although several studies propose a tumor suppressor role for the actin bundling protein myopodin, it was also shown previously that overexpression of mouse myopodin promotes invasion in vitro. In the present study, the role of myopodin in human cancer cell motility and invasion was explored using RNA interference with siRNA duplexes designed to down-regulate all human myopodin isoforms currently identified. We show that down-regulation of myopodin expression in human cancer cells significantly reduces the invasive properties of these cells both in collagen type I and in Matrigel. Furthermore, the motile characteristics of cancer cells are also curbed by reduced myopodin expression whereas cell-cell contacts are reinforced. These results point to a role for myopodin as tumor activator. While these findings are at variance with the suggested tumor suppressor role for myopodin, we hypothesize that the subcellular localization of the protein is involved in its suppressor or activator function in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360353

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Myopodin is an F-actin bundling protein with multiple independent actin-binding regions.

Authors:  Anja Linnemann; Padmanabhan Vakeel; Eduardo Bezerra; Zacharias Orfanos; Kristina Djinović-Carugo; Peter F M van der Ven; Gregor Kirfel; Dieter O Fürst
Journal:  J Muscle Res Cell Motil       Date:  2012-12-09       Impact factor: 2.698

2.  Gene expression profiling in male genital lichen sclerosus.

Authors:  Emma Edmonds; Geraint Barton; Sandrine Buisson; Nick Francis; Frances Gotch; Laurence Game; Munther Haddad; Michael Dinneen; Chris Bunker
Journal:  Int J Exp Pathol       Date:  2011-06-30       Impact factor: 1.925

Review 3.  Synaptopodin family of natively unfolded, actin binding proteins: physical properties and potential biological functions.

Authors:  Joseph M Chalovich; Mechthild M Schroeter
Journal:  Biophys Rev       Date:  2010-11-20

4.  Synaptopodin-2 induces assembly of peripheral actin bundles and immature focal adhesions to promote lamellipodia formation and prostate cancer cell migration.

Authors:  FuiBoon Kai; James P Fawcett; Roy Duncan
Journal:  Oncotarget       Date:  2015-05-10

5.  YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells.

Authors:  Xia Sheng; Wen-Bin Li; De-Lin Wang; Ke-Hong Chen; Jian-Jia Cao; Zhao Luo; Jiang He; Mei-Cai Li; Wu-Jiang Liu; Chao Yu
Journal:  Mol Med Rep       Date:  2015-06-29       Impact factor: 2.952

6.  Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics data.

Authors:  Chen Chen; Li-Guo Zhang; Jian Liu; Hui Han; Ning Chen; An-Liang Yao; Shao-San Kang; Wei-Xing Gao; Hong Shen; Long-Jun Zhang; Ya-Peng Li; Feng-Hong Cao; Zhi-Guo Li
Journal:  Onco Targets Ther       Date:  2016-03-16       Impact factor: 4.147

7.  The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer.

Authors:  Sofia Lage-Vickers; Juan Bizzotto; Maria Pia Valacco; Pablo Sanchis; Sergio Nemirovsky; Estefania Labanca; Carlos Scorticati; Osvaldo Mazza; Antonina Mitrofanova; Nora Navone; Elba Vazquez; Javier Cotignola; Geraldine Gueron
Journal:  Commun Biol       Date:  2021-01-22

8.  Synaptopodin-2 plays an important role in the metastasis of breast cancer via PI3K/Akt/mTOR pathway.

Authors:  Erjie Xia; Xiaofen Zhou; Adheesh Bhandari; Xiaohua Zhang; Ouchen Wang
Journal:  Cancer Manag Res       Date:  2018-06-18       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.